Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Investment
    • Indian Genetics...

    Indian Genetics startup MedGenome raises Rs 415 crore in funding led by LeapFrog Investments

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-04-03T14:17:28+05:30  |  Updated On 3 April 2020 2:17 PM IST
    Indian Genetics startup MedGenome raises Rs 415 crore in funding led by LeapFrog Investments

    New Delhi: Genetic diagnostics firm MedGenome has said it has raised USD 55 million (over Rs 415 crore) in funding led by LeapFrog Investments.

    Existing investors Sofina and Sequoia also participated in the round.

    The funds will be utilized to expand access and affordability of genetic testing services across India, it added.

    Globally the investment will drive the creation of more diverse datasets and enable discovery of novel drug targets, MedGenome said in a statement.

    "Genomics and personalized medicine are the future of healthcare, but emerging markets remain significantly under-penetrated. As the largest player in India in applied genomics, we are well-positioned to fill this gap," MedGenome CEO and Founder Sam Santhosh said.

    MedGenome has completed over 2,00,000 genomic tests to date and obtains samples from more than 550 hospitals and 6,000 clinicians across India, the company said.

    This investment will expand the clinical genomic testing market by expanding access in tier-II and tier-III towns and cities across India and accelerate the company's drug discovery programs, it added.

    "We are very excited to partner with MedGenome to increase access to affordable and high-quality genetic testing for emerging consumers in Asia and Africa," Global Co-Lead for healthcare investments at LeapFrog Felix Olale said.

    Genomic sequencing will anchor the future of medicine and "we must include other under-represented genomes not only because it drives access, but also because it improves the accuracy for everyone, he added.

    Read also: MedGenome receives accreditation from the College of American Pathologists



    genetic-diagnosticsmedgenomeleapfrog-investmentssam-santhosh
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok